<DOC>
	<DOC>NCT01802697</DOC>
	<brief_summary>This is a first in man study to assess safety and tolerability of the IgG cleaving enzyme Immunoglobuli G degrading enzyme of streptococcus pyogenes (IdeS).</brief_summary>
	<brief_title>Safety Study on IdeS in Healthy Volounteers</brief_title>
	<detailed_description>A phase I study (11-HMedIdeS-01, EudraCT no. 2012-000 969-21) first in man single ascending dose study in 29 healthy subjects to investigate if IdeS is safe and well tolerated in doses up to 0.24 mg/kg body weight (BW).</detailed_description>
	<criteria>Ability to understand and sign informed consent BMI 1930 Clinically significant disease Positive HIV, hepatistis B or C Drug abuse Smoking Use of medication except paracetamol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>volunteers</keyword>
</DOC>